Last10K.com

Bellerophon Therapeutics, Inc. (BLPH) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019

Bellerophon Therapeutics, Inc.

CIK: 1600132 Ticker: BLPH
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2019
Apr. 03, 2020
Jun. 30, 2019
Document and Entity Information   
Entity Registrant NameBellerophon Therapeutics, Inc.  
Entity Central Index Key0001600132  
Document Type10-K  
Document Period End DateDec. 31, 2019  
Amendment Flagfalse  
Current Fiscal Year End Date--12-31  
Entity Current Reporting StatusYes  
Entity Filer CategoryNon-accelerated Filer  
Entity Common Stock, Shares Outstanding 6,132,393 
Entity Small Businesstrue  
Entity Emerging Growth Companytrue  
Entity Shell Companyfalse  
Entity Ex Transition Periodtrue  
Document Fiscal Year Focus2019  
Document Fiscal Period FocusFY  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Interactive Data CurrentYes  
Entity Public Float  $ 16.0

View differences made from one year to another to evaluate Bellerophon Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Bellerophon Therapeutics, Inc..

Continue

Assess how Bellerophon Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Bellerophon Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Financial
Revenue
Other
Filter by Subcategory:
All
Expense
Cash Flow
Product
Shares
Dividend
Other
Inside Bellerophon Therapeutics, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Stockholders' Equity (Deficiency In Assets)
Consolidated Statements Of Changes In Stockholders' Equity (Deficiency In Assets) (Parenthetical)
Consolidated Statements Of Comprehensive (Loss) Income
Consolidated Statements Of Operations
- Right-Of-Use Asseta (Details)
Commitments And Contingencies
Commitments And Contingencies (Narrative) (Details)
Commitments And Contingencies (Operating Lease Obligations) (Details)
Commitments And Contingencies (Tables)
Common Stock Warrants
Common Stock Warrants (Narrative) (Details)
Common Stock Warrants (Tables)
Common Stock Warrants (Warrant Activity) (Details)
Fair Value Measurements
Fair Value Measurements (Hierarchy) (Details)
Fair Value Measurements (Tables)
Fair Value Measurements (Weighted Average Assumptions) (Details)
Income Taxes
Income Taxes (Deferred Tax Assets And Liabilities) (Details)
Income Taxes (Narrative) (Details)
Income Taxes (Reconciliation Of Effective Income Tax Rate) (Details)
Income Taxes (Tables)
Leases (Tables)
Liquidity
Liquidity (Details)
Net (Loss) Income Per Share
Net (Loss) Income Per Share (Antidilutive Securities) (Details)
Net (Loss) Income Per Share (Earnings Per Share) (Details)
Net (Loss) Income Per Share (Tables)
Organization And Nature Of The Business
Organization And Nature Of The Business (Details)
Property And Equipment
Property And Equipment (Details)
Property And Equipment (Tables)
Quarterly Financial Data (Unaudited)
Quarterly Financial Data (Unaudited) (Details)
Quarterly Financial Data (Unaudited) (Tables)
Right Of Use Assets And Leases
Right Of Use Assets And Leases - Narrative (Details)
Stock-Based Compensation
Stock-Based Compensation (Allocation Of Period Costs) (Details)
Stock-Based Compensation (Fair Value Of Options Issued) (Details)
Stock-Based Compensation (Ikaria Equity Incentive Plan) (Details)
Stock-Based Compensation (Narrative) (Details)
Stock-Based Compensation (Option Activity) (Details)
Stock-Based Compensation (Restricted Stock Activity) (Details)
Stock-Based Compensation (Tables)
Subsequent Events (Details)
Subsequent Events Subsequent Events
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Ticker: BLPH
CIK: 1600132
Form Type: 10-K Annual Report
Accession Number: 0001600132-20-000039
Submitted to the SEC: Mon Apr 06 2020 8:27:07 AM EST
Accepted by the SEC: Mon Apr 06 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/blph/0001600132-20-000039.htm